Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Octaplex

Phase 3Small molecule

1

Indications

4

Total Trials

0

Active Trials

0

Competitors

Clinical

Trials by Indication[1]

Anticoagulation1 trial

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Completed· Octapharma logo

Octapharma·Phase 3·NCT02740335·208 enrolled

Cardiac Surgery1 trial

Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

Completed· Octapharma logo

Octapharma·Phase 3·NCT05523297·420 enrolled

Invasive Procedure1 trial

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

Completed· Octapharma logo

Octapharma·Phase 3·NCT00618098·200 enrolled

Bleeding1 trial

Study of Four-factor Prothrombin Complex Concentrate, OCTAPLEX, in Patients With Acute Major Bleeding on Direct Oral Anticoagulant (DOAC) Therapy With Factor Xa Inhibitor

Terminated· Octapharma logo

Octapharma·Phase 3·NCT04867837·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Octaplex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Octaplex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Octaplex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Octapharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Octapharma

Related News